Introduction
It is known that endothelial release of nitric oxide (NO) acts as a physiological regulator of vascular tone and blood pressure. 1- Because NO is also produced by several types of pulmonary cells, 4, 5 it may be found in respiratory bronchioli and alveoli. The increased production of NO, found in exhaled air of asthmatic patients, reflects the role of endogenous nitric oxide as a modulator of bronchial tone. 6, 7 Consequently, airway epithelium plays the same role as endothelium in regulating the tone of underlying smooth muscle. Recently, a modulatory effect of epithelium on the contractile responses of airway smooth muscle to spasmogens has been described. Airway epithelium plays this critical role in the regulation of airway functions producing not only nitric oxide, but also a large number of inflammatory mediators, including prostaglandins, endothelin-1, and various cytokines. By releasing NO, the epithelial layer acts as a protective barrier against spasmogenic agents that are released in inflammatory disorders.
As suggested by Nijkamp et al., diminished production of NO after epithelial damage, typical of asthma, contributes to airway hyperresponsiveness, which may be due to a marked release of platelet activating factor (PAF), a typical inflammatory and allergic mediator of asthma. 1 PAF is a potent bronchoconstrictor, and also induces strong pulmonary hypertension and systemic hypotension.
Moritoki et al. 11 have suggested that this systemic hypotension can be due to production of nitric oxide.
The aim of this present study was to evaluate the role of endogenous NO on circulatory and respiratory systems and its involvement in PAF-induced shock and bronchoconstriction. To evaluate the role of endogenous NO in the normal pig or during PAFdependent shock, we used N-nitro-t-arginine methyl ester (t-NAME), an arginine analogue, which acts as an inhibitor of NO synthesis.
Materials and Methods
Six Large White In pigs pretreated with t-NAME, the PAF-dependent rise in Est,t and Edyn, was similar to that observed without t-NAME. As for lung resistances, pretreatment with indomethacin associated with t-NAME prevented PAF-dependent changes in static and dynamic elastances. Figure 3 shows the correlation between Est,t and MPAP. The increases in MPAP and Est,,. caused by t-NAME or by PAF were similar. When PAF was administered after pretreatment with t-NAME, the Our data also seem to suggest that the sensitivity to NO differs in the pulmonary and systemic vascular beds. After t-NAME administration MPAP increased, while the systemic blood pressure did not. The increase in MPAP after block of endogenous NO confirms the data of Persson et al. 16 showing that pulmonary vascular tone is regulated by nitric oxide. Even though it is not possible to exclude a difference in NO sensitivity in the two vascular districts, it seems probable that the systemic vasoconstrictor effect is masked by the marked decrease in CO consequent to an impairment of cardiac activity. The latter effect may be caused by a sustained coronary vasoconstriction due to an inhibition of NO synthesis. It is known that NO is produced continuously by coronary endothelium 17 (Fig. 3) . The rise in MPAP due to t-NAME administration is correlated with a change in elastance even when respiratory resistance does not change. The In conclusion, this study shows that NO is released by both endothelial and epithelial cells. Inhibition of NO synthesis by t-NAME administration increases the inflammatory cell accumulation induced by PAF. 25 Thus, nitric oxide may be considered an endogenous defensive mechanism against inflammatory, obstruc-tive and hypertensive lung diseases, and may be an important factor in the regulation of airway hyperresponsiveness and in the maintenance of bronchial tone. 26, 27 
